ChemoCentryx (CCXI) Announces Interim ORR Data from CCX872 Phase 1b in Adv. Pancreatic Cancer
Tweet Send to a Friend
ChemoCentryx, Inc., (Nasdaq: CCXI) announced initial 12 week overall response rate (ORR) results from an ongoing open label, single arm ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE